Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with <i>EGFR</i> Mutations

Abstract

Aromatase is a candidate prognostic factor in patients with lung adenocarcinoma, especially in those with EGFR mutations, and may also be a beneficial therapeutic target in those patients.